Tablet press investment at Juniper Pharma Services
Latest addition to the company's suite of tablet manufacturing equipment enables the CDMO to produce single and bi-layer tablets in multiple tooling formats.
Juniper Pharma Services has bolstered its tablet manufacturing capabilities following the purchase and validation of an additional tablet press.
The investment by the UK-based contract development and manufacturing organisation (CDMO) significantly extends its tablet production capacity and further strengthens the company’s ability to support clients’ clinical needs.
Its new RoTab tablet press by kg-pharma is designed specifically for batch sizes from 50g to 50kg and allows Juniper Pharma Services to produce up to 42,000 tablets per hour. This latest addition to its suite of tablet manufacturing equipment enables the CDMO to produce single and bi-layer tablets in multiple tooling formats.
The tablet press is the latest in a string of recent equipment investments by the CDMO and comes just weeks after the company announced significant expansion to its spray drying, topical, and semi-solid capabilities.
Ian Lafferty, VP of operations at Juniper Pharma Services, said: “The installation of this additional tablet press machine takes both our capability to produce different tablet types, and our output capacity, to a new level.
“This fully instrumented machine provides real time compression data, allowing our team to provide invaluable understanding during the optimisation of clients’ tablet formulations, enabling a smooth transition from pilot scale to commercial high speed tablet manufacturing.”
Juniper Pharma Services develops and produces oral and topical drug products for clinical trials and is able to optimise formulation performance through its team’s science-led approach to projects.
Dr Lafferty added: “We continue to expand our support to pharmaceutical and biotechnology companies across the globe, especially to those with significant formulation challenges requiring the integrated skills of a problem-to-solution minded development team.
“Our recent investments have strategically expanded and extended our development and manufacturing capabilities to ensure we are equipped to support drug development at a clinical scale, while also giving a commercially robust and replicable process.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance